2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 292

Clinical Utility of Anti-CADM-140/Melanoma Differentiation-Associated Gene 5 Autoantibody Titers in Patients with Juvenile Dermatomyositis and Rapidly Progressive Interstitial Lung Disease
Abstract Number: 2402

Clinical Utility of the Hospital Anxiety and Depression Scale for an Outpatient Fibromyalgia Education Program
Abstract Number: 650

Clinical Variables Associated with Thrombosis At Systemic Lupus Erythematosus Diagnosis. Differences Between Patients with Positive/Negative Lupus Anticoagulant
Abstract Number: 206

Clinical, Laboratory, and Cellular Responses in the Rituximab in Myositis Trial in Patients Enrolled At the National Institutes of Health
Abstract Number: 2550

Clinical, Radiographic, and Immunogenic Effects After 1 Year of Tocilizumab-Based Treatment Strategy with and without Methotrexate in Rheumatoid Arthritis: The ACT-RAY Study
Abstract Number: 255

Clinically Meaningful Effect of Strontium Ranelate On Knee Osteoarthritis Symptoms
Abstract Number: 2552

Clinically Significant and Biopsy-Documented Renal Involvement in Primary Sjögren’s Syndrome: Clinical Presentation and Outcome
Abstract Number: 305

Clinicopathologic Correlates for Activity and Damage of Lupus Nephritis in Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 1137

Clinimetric Properties of a New Outcome Measure:the Hand-Osteoarthritis Aesthetic Damage Index
Abstract Number: 1918

Cluster Analysis of Organ Involvements Patients with Serum IgG4 Elevation; IgG4–related Disease Is a Distinct Subtype of Patients with Hyper-IgG4
Abstract Number: 1554

Clusters of Fatigue- a Comparison Between Persons with Systemic Lupus Erythematosus and Age and Gender Matched Controls
Abstract Number: 1001

CNstream2: Improved SNP and CNV Genotyping Reveals New Loci Associated with Rheumatic Diseases
Abstract Number: 134

Co-Existence of Gout in Rheumatoid Arthritis: It Does Happen! A Population Based Study
Abstract Number: 661

Co-Localization of C-Reactive Protein, Immunoglobulin G and Complement in Renal Subendothelial Immune Deposits of Proliferative Lupus Nephritis Detected Using Immunogold Electron Microscopy
Abstract Number: 1322

Coadministration of ASP015K, a Novel Janus Kinase Inhibitor with Methotrexate Demonstrates Tolerability and Lack of Pharmacokinetic Interactions in Patients with Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].